In Reply:

Abstract

The author(s) indicated no potential conflicts of interest. REFERENCES 1. Scartozzi M, Bearzi I, Pierantoni C, et al: Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 25:3930-3935, 2007 2. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 3. Abdel-Latif MM, O'Riordan J, Windle HJ, et al: NF-kB activation in esophageal adenocarcinoma relationship to Barret's metaplasia, survival and response to neoadjuvant chemoradiotherapy. Ann Surg 239:491-500, 2004 4. Izzo JG, Malhotra U, Wu T-T, et al: Association of activated transcription factor nuclear factor kB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24:748-754, 2006 5. Dolcet X, Llobet D, Pallares J, et al: NF-kB in development and progression of human cancer. Virchows Arch 446:475-482, 2005 6. Bours V, Bentires-Alj M, Hellin AC, et al: Nuclear factor-kB, cancer and apoptosis.